Viropharma, Inc. (VPHM) Tops Q3 EPS by 23c; Guides FY11 Cinryze Net Sales
Tweet
Share
E-mailGet Alerts VPHM Hot Sheet
Join SI Premium – FREE
Viropharma, Inc. (NASDAQ: VPHM) reported Q3 EPS of $0.56, $0.23 better than the analyst estimate of $0.33. Revenue for the quarter came in at $143 million versus the consensus estimate of $129.47 million.
Sees FY11 Cinryze net sales to be between $250 and $260 million.
Sees FY11 Cinryze net sales to be between $250 and $260 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
- Reading (RDI) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
